European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A
DOI:
https://doi.org/10.2340/16501977-2877Keywords:
Intrathecal baclofen, Botulinum toxin, Spasticity, Selection criteria, Focal, Generalised, SegmentalAbstract
Objective: To develop an algorithm for the selection of adults with disabling spasticity for treatment with intrathecal baclofen (ITB) and/or botulinum toxin type A (BoNT A).
Methods: A European Advisory Board of 4 neurologists and 4 rehabilitation specialists performed a literature review on ITB and BoNT A treatment for disabling spasticity. An online survey was sent to 125 physicians and 13 non-physician spasticity experts. Information on their current clinical practice and level of agreement on proposed selection criteria was used to inform algorithm design. Consensus was considered reached when ≥75% of respondents agreed or were neutral.
Results: A total of 79 experts from 17 countries completed the on-line survey (57%).
Agreement was reached that patients with multi-segmental or generalized disabling spasticity refractory to oral drugs are the best candidates for ITB (96.1% consensus), while those with focal/segmental disabling spasticity are ideal candidates for BoNT A (98.7% consensus). In addition the following are good candidates for ITB (% consensus): bilateral disabling spasticity affecting lower limbs only (97.4%), bilateral (100%) or unilateral (90.9%) disabling spasticity affecting lower limbs and trunk, and unilateral or bilateral disabling spasticity affecting upper and lower extremities (96.1%).
Conclusion: This algorithm will support the management of adult patients with disabling spasticity by aiding patient selection for ITB and/or BoNT A treatments.
Lay Abstract
Involuntary muscle overactivity or spasticity is the increase in muscle tone caused as a consequence of a brain or spine lesion. The muscle overactivity can become disabling spasticity and adequate treatment or combination of treatments are essential to reduce or eliminate the problems and disability caused by the involuntary muscle overactivity. An European expert consensus on the treatment of disabling spasticity, with Intrathecal Baclofen (an implanted pump that delivers baclofen directly near the spinal cord) or injection of Botulinum Toxin into muscles, was made using an online survey with 79 experts completing the survey. This algorithm supports the future management of adult patients with disabling muscle overactivity by aiding patient selection for Intrathecal Baclofen and/or Botulinum Toxin treatment.
Downloads
References
Schiess M, Eldabe S, Konrad P, Molus L, Spencer R, Stromberg K, et al. Intrathecal baclofen for severe spasticity: longitudinal data from the product surveillance registry. Neuromodulation 2020; 23: 996-1000. https://doi.org/10.1111/ner.13097
Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005; 27: 2-6. https://doi.org/10.1080/09638280400014576
Opheim A, Danielsson A, Alt Murphy M, Persson H, Sunnerhagen K. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil 2014; 93: 884-896. https://doi.org/10.1097/PHM.0000000000000157
Natale M, Mirone G, Rotondo M, Moraci A. Intrathecal baclofen therapy for severe spasticity: Analysis on a series of 112 consecutive patients and future prospectives. Clin Neurol Neurosurg 2012; 114: 321-325. https://doi.org/10.1016/j.clineuro.2011.10.046
Draulans N, Vermeersch K, Degraeuwe B, Meurrens T, Peers K, Nuttin B, et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil 2013; 27: 1137-1143. https://doi.org/10.1177/0269215513488607
Mathur S, Chu S, McCormick Z, Chang Chien G, Marciniak C. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. Phys Med Rehabil 2014; 6: 506-513. https://doi.org/10.1016/j.pmrj.2013.12.005
Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R. Intrathecal baclofen for multiple sclerosis related spasticity: a twenty year experience. Mult Scler Relat Disord 2019; 27: 95-100. https://doi.org/10.1016/j.msard.2018.10.009
Barney CC, Merbler AM, Stansbury J, Krach LE, Partington M, Graupman P, et al. Musculoskeletal pain outcomes pre- and post intrathecal baclofen pump implant in children with cerebral palsy: a prospective cohort study. Arch Rehabil Res Clin Transl 2020; 2: 100049.
https://doi.org/10.1016/j.arrct.2020.100049
Schiess MC, Eldabe S, Konrad P, Molus L, Spencer R, Stromberg K, et al. Intrathecal baclofen for severe spasticity: longitudinal data from the product surveillance registry. Neuromodulation 2020; 23: 996-1002. https://doi.org/10.1111/ner.13097
Dan B, Motta F, Vles J, Vloeberghs M, Becher J, Eunson P, et al. Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol 2010; 14: 19-28. https://doi.org/10.1016/j.ejpn.2009.05.002
Saulino M, Ivanhoe C, McGuire J, Ridley B, Shilt J, Boster A. Best practices for intrathecal baclofen therapy: patient selection. Neuromodulation 2016; 19: 607-615. https://doi.org/10.1111/ner.12447
Bensmail D, Wissel J, Laffont I, Simon O, Scheschonka A, Flatau-Baqué B, et al. Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. Ann Phys Rehabil Med 2020; 0-6. https://doi.org/10.2340/16501977-2651
Hara T, Abo M, Hara H, Sasaki N, Yamada N, Niimi M, et al. The effect of repeated botulinum toxin a therapy combined with intensive rehabilitation on lower limb spasticity in post-stroke patients. Toxins (Basel) 2018; 10: 349. https://doi.org/10.3390/toxins10090349
Francisco G, Balbert A, Bavikatte G, Bensmail D, Carda S, Deltombe T, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: an international group consensus. J Rehabil Med 2021; 53: jrm00134.
https://doi.org/10.2340/16501977-2753
Ashford S, Turner Stokes L, Allison R, Duke L, Bavikatte G, Kirker S, et al. Spasticity in adults: management using botulinum toxin - National Guidelines 20 March 2018. [cited 2021 Jul 7]. Available from: https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin
Fheodoroff K, Rekand T, Medeiros L, Koßmehl P, Wissel J, Bensmail D, et al. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. Health Qual Life Outcomes 2020; 18: 1-10. https://doi.org/10.1186/s12955-020-01304-4
Esquenazi A, Wein TH, Ward AB, Geis C, Liu C, Dimitrova R. Optimal muscle selection for onabotulinumtoxina injections in poststroke lower-limb spasticity: a randomized trial. Am J Phys Med Rehabil 2019; 98: 360-368. https://doi.org/10.1097/PHM.0000000000001101
Gonnade N, Lokhande V, Ajij M, Gaur A, Shukla K. Phenol versus botulinum toxin a injection in ambulatory cerebral palsy spastic diplegia: a comparative study. Pediatr Neurosci 2018; 13: 176-181. https://doi.org/10.4103/JPN.JPN_123_17
Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type a in adult spasticity. J Rehabil Med 2009; 41: 13-25. https://doi.org/10.2340/16501977-0303
Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity the TOWER study. Neurology 2017; 88: 1321-1328. https://doi.org/10.1212/WNL.0000000000003789
Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A. Heart rate variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (NT-201) injection. Eur J Phys Rehabil Med 2015; 51: 353-359. https://doi.org/10.1016/j.rehab.2014.03.170
Qualtrics Surveys - Qualtrics XM Software. [cited 2021 Jul 7]. Available from: https://www.qualtrics.com/qualtrics/xm%0A
Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014; 67: 401-409. https://doi.org/10.1016/j.jclinepi.2013.12.002
Guideline for the treatment of cerebral and/or spinal spasticity in adults (2017). Last review 01.01.2016 Federatie Medisch Specialisten: Netherlands Society of Rehabilitation Medicine (NSRM), The Netherlands. [cited 2021 May 13]. Available from: https://revalidatiegeneeskunde.nl/article/richtlijn-behandeling-van-cerebrale-enof-spinale-spasticiteit-bij-volwassenen-gepubliceerd
Burns AS, Lanig I, Grabljevec K, New PW, Bensmail D, Ertzgaard P, et al. Optimizing the management of disabling spasticity following spinal cord damage: The Ability Network - an international initiative. Arch Phys Med Rehabil 2016; 97: 2222-2228. https://doi.org/10.1016/j.apmr.2016.04.025
Fheodoroff K, Scheschonka A, Wissel J. Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. Disabil Rehabil 2020; 17: 1-7. https://doi.org/10.1080/09638288.2020.1804627
Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, et al. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry 2018; 89: 642-650. https://doi.org/10.1136/jnnp-2017-317021
Schiess MC, Oh IJ, Stimming EF, Lucke J, Acosta F, Fisher S, et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation 2011; 14: 38-45. https://doi.org/10.1111/j.1525-1403.2010.00308.x
Sammaraiee Y, Stevenson VL, Keenan E, Buchanan K, Lee H, Padilla H, et al. Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity. Mult Scler Relat Disord 2020; 46: 102503. https://doi.org/10.1016/j.msard.2020.102503
Ivanhoe C, Francisco G, McGuire J, Subramanian T, Grissom S. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006; 87: 1509-1515. https://doi.org/10.1016/j.apmr.2006.08.323
Hara T, Abo M, Hara H, Kobayashi K, Shimamoto Y, Samizo Y, et al. Effects of botulinum toxin A therapy and multidisciplinary rehabilitation on upper and lower limb spasticity in post-stroke patients. Int J Neurosci 2017; 127: 469-478. https://doi.org/10.1080/00207454.2016.1196204
Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm 2015; 122: 1283-1287. https://doi.org/10.1007/s00702-015-1384-6
Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm 2015; 122: 327-333. https://doi.org/10.1007/s00702-014-1252-9
Yoon YK, Lee KC, Cho HE, Chae M, Chang JW, Chang WS, et al. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Med (United States) 2017; 96: e7472. https://doi.org/10.1097/MD.0000000000007472
Abbatemarco JR, Griffin A, Jones NG, Hartman J, McKee K, Wang Z, et al. Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: a single-center experience. Mult Scler J 2020; 1-9. https://doi.org/10.1177/1352458520936912
Lee BS, Jones J, Lang M, Achey R, Dai L, Lobel DA, et al. Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis. J Neurosurg 2018; 129: 1056-1062. https://doi.org/10.3171/2017.5.JNS162925
Pucks-Faes E, Hitzenberger G, Matzak H, Fava E, Verrienti G, Laimer I, et al. Eleven years' experience with intrathecal baclofen - complications, risk factors. Brain Behav 2018; 8: 1-9. https://doi.org/10.1002/brb3.965
Motta F, Antonello CE. Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications. J Neurosurg Pediatr 2016; 18: 493-498. https://doi.org/10.3171/2016.4.PEDS15646
Bayhan IA, Sees JP, Nishnianidze T, Rogers KJ, Miller F. Infection as a complication of intrathecal baclofen treatment in children with cerebral palsy. J Pediatr Orthop 2016; 36: 305-309. https://doi.org/10.1097/BPO.0000000000000443
Imerci A, Rogers KJ, Pargas C, Sees JP, Miller F. Identification of complications in paediatric cerebral palsy treated with intrathecal baclofen pump: a descriptive analysis of 15 years at one institution. J Child Orthop 2019; 13: 529-535. https://doi.org/10.1302/1863-2548.13.190112
Baricich A, Wein T, Cinone N, Bertoni M, Picelli A, Chisari C, et al. BoNT-A for post-stroke spasticity: guidance on unmet clinical needs from a Delphi panel approach. Toxins (Basel) 2021; 13: 1-12. https://doi.org/10.3390/toxins13040236
Pucks-Faes E, Hitzenberger G, Matzak H, Verrienti G, Schauer R, Saltuari L. Intrathecal baclofen in paroxysmal sympathetic hyperactivity: Impact on oral treatment. Brain Behav 2018; 8: e01124. https://doi.org/10.1002/brb3.1124
Harb A, Kishner S. Modified Ashworth Scale. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 May 9.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Bo Biering-Soerensen, Val Stevenson, Djamel Bensmail, Klemen Grabljevec, Mercedes Martínez Moreno, Elke Pucks-Faes, Joerg Wissel, Mauro Zampolini
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
